<!DOCTYPE html PUBLIC "-//w3c//dtd html 4.0 transitional//en">

<html>
<head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="Microsoft Word 97" name="Generator"/>
<meta content="C:\Programme\Microsoft Office\Office\html.dot" name="Template"/>
<meta content="Mozilla/4.76 [en] (Windows NT 5.0; U) [Netscape]" name="GENERATOR"/>
<meta content="Jg Reichen" name="Author"/>
<meta content="Medical" name="Classification"/>
<meta content="Diagnosis and treatment of acute hepatitis C" name="Description"/>
<meta content="hepatitis C, acute, chronic, natural history" name="KeyWords"/>
<title>Acute hepatitis C</title>
</head>
<body alink="#FF0000" background="BLUE_PAP-32.GIF" bgcolor="#FFFFFF" link="#0000FF" text="#000000" vlink="#800080">
<center>
<b><font size="+3">ACUTE HEPATITIS C</font></b>
<br/>
<b><font size="+1"><a href="/cache?uri=https%3A%2F%2Fwww.cx.unibe.ch%2Fikp%2Flab2%2Fjr.html&amp;index=cw09&amp;raw">J. Reichen M.D.</a></font></b>
<br/>
<b><font size="+1">Department Clinical Pharmacology, University of Berne, Switzerland</font></b>
<br/>
<hr width="100%"/>
</center>
<ul>
<ul type="DISC">
<li> <b><font size="+1">About 20 % of patients with acute hepatitis C become jaundiced; this is often accompanied by a syndrome of fatigue, myalgias, low-grade fever, nausea and vomiting (12).</font></b></li>
<li> <b><font size="+1">Acute hepatitis C frequently (43 - 77 %, see table) becomes chronic. A study published only in abstract form reported that 23/50 patients cleared the virus spontaneously within 12 weeks; this occurred more frequently in symptomatic patients (13). Similarly, a recent study from Austria reported spontaneous clearance in 8/12 patients (15); in this study, a rapid fall in HCV-RNA predicted spontaneous clearance.</font></b></li>
</ul>
</ul>
<center>
<table bgcolor="#FFCC99" border="" bordercolor="#000000" cellpadding="4" width="614">
<tbody>
<tr>
<td valign="TOP" width="15%">
<center>
<b>Reference</b>
</center> </td>
<td valign="TOP" width="6%">
<center>
<b>n</b>
</center> </td>
<td valign="TOP" width="54%">
<center>
<b>Setting</b>
</center> </td>
<td valign="TOP" width="25%">
<center>
<b>% chronic</b>
</center> </td>
</tr>
<tr>
<td valign="TOP" width="15%"><i>(</i><b>1)</b></td>
<td valign="TOP" width="6%"><b>41</b></td>
<td valign="TOP" width="54%"><b>Posttransfusion</b></td>
<td valign="TOP" width="25%"><b>73 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(2)</b></td>
<td valign="TOP" width="6%"><b>70</b></td>
<td valign="TOP" width="54%"><b>Acute hepatitis, for C mostly IVDA</b></td>
<td valign="TOP" width="25%"><b>60 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(3)</b></td>
<td valign="TOP" width="6%"><b>60</b></td>
<td valign="TOP" width="54%"><b>Acute hepatitis</b></td>
<td valign="TOP" width="25%"><b>77 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(4)</b></td>
<td valign="TOP" width="6%"><b>32</b></td>
<td valign="TOP" width="54%"><b>Acute hepatitis, mostly post-transfusion</b></td>
<td valign="TOP" width="25%"><b>66 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(5)</b></td>
<td valign="TOP" width="6%"><b>24</b></td>
<td valign="TOP" width="54%"><b>Posttranfusion, selected sample</b></td>
<td valign="TOP" width="25%"><b>66 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(6)</b></td>
<td valign="TOP" width="6%"><b>21</b></td>
<td valign="TOP" width="54%"><b>Acute hepatitis</b></td>
<td valign="TOP" width="25%"><b>43 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(7)</b></td>
<td valign="TOP" width="6%"><b>51</b></td>
<td valign="TOP" width="54%"><b>Immunoglobulin exposure</b></td>
<td valign="TOP" width="25%"><b>45 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(8)</b></td>
<td valign="TOP" width="6%"><b>97</b></td>
<td valign="TOP" width="54%"><b>Community-acquired acute hepatitis</b></td>
<td valign="TOP" width="25%"><b>62 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(9)</b></td>
<td valign="TOP" width="6%"><b>96</b></td>
<td valign="TOP" width="54%"><b>Acute hepatitis</b></td>
<td valign="TOP" width="25%"><b>63 %</b></td>
</tr>
<tr>
<td valign="TOP" width="15%"><b>(10)</b></td>
<td valign="TOP" width="6%"><b>81</b></td>
<td valign="TOP" width="54%"><b>Exposure to Rh-Hyperimmunoglobulin</b></td>
<td valign="TOP" width="25%"><b>69 %</b></td>
</tr>
<tr>
<td><b>(15)</b></td>
<td><b>12</b></td>
<td><b>Different</b></td>
<td><b>33 %</b></td>
</tr>
</tbody>
</table>
</center>
<ul>
<ul type="DISC">
<li> <b><font size="+1">Diagnosis should be done determining HCV RNA since development of anti-HCV is delayed (4 - 8 weeks); HCV RNA becomes detectable 1 - 3 weeks after exposure (12), anti-HCV within 20 - 150 days. ALT is elevated usually at week 4. Importantly, during acute hepatitis C, HCV RNA fluctuates widely and may even be negative (12).</font></b></li>
<li> <b><font size="+1">A <a href="/cache?uri=https%3A%2F%2Fwww.ikp.unibe.ch%2Flab2%2Fhepc%2Fsld039.htm&amp;index=cw09&amp;raw">meta-analysis</a> shows that treatment with a 3 month of interferon diminishes chronicity (11).Â  Jaeckel and colleagues (14) - in an unfortunately uncontrolled study - prevented chronicity in 43/44 patients with an intensive interferon regimen: Interferon 5 MU s.c. daily during 4 weeks followed by 5 MU thrice weekly during 20 weeks. Although there are no studies to this effect, I would recommend combination treatment with a pegylated interferon + ribavirin.</font></b></li>
</ul>
</ul>
<blockquote>
<b><u>References</u></b>
<ol>
<li> Barrera JM, Bruguera M, Ercilla MG, et al. (1995). Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 21:639-44.</li>
<li> Buti M, Jardi R, Rodriguezfrias F, et al. (1994). Etiology of acute sporadic hepatitis in Spain: the role of hepatitis C and E viruses. J Hepatol 20:589-92.</li>
<li> Giuberti T, Ferrari C, Marchelli S, et al. (1992). Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. Liver 12:94-9.</li>
<li> Hino K, Sainokami S, Shimoda K, et al. (1994). Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci 39:19-27.</li>
<li> Mattson L, Sonnerborg A, Weiland O. (1993). Outcome of Acute Symptomatic Non-A, Non-B Hepatitis - A 13- Year Follow-Up Study of Hepatitis-C Virus Markers. Liver 13:274-8.</li>
<li> Missale G, Bertoni R, Lamonaca V, et al. (1996). Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti- viral cell-mediated immune response. J Clin Invest 98:706-14.</li>
<li> Zibert A, Meisel H, Kraas W, et al. (1997). Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 25(5):1245-9.</li>
<li> Alter MJ, Margolis HS, Krawczynski K, et al. (1992). The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327:1899-905.</li>
<li> Tassopoulos NC, Hatzakis A, Delladetsima I, et al. (1992). Role of hepatitis C virus in acute non-A- non-B hepatitis in Greece: a 5-year prospective study. Gastroenterology 102:969-72.</li>
<li> Dittmann S, Roggendorf M, Duerkop J, et al. (1991). Long-term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol 13:323-7.</li>
<li> Poynard T, Leroy V, Cohard M et al. (1996). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24: 778-789.</li>
<li> <b>Orland JR, Wright TL, Cooper S (2001). Acute hepatitis C. Hepatology 33: 321-327. (Recommended review)</b>.</li>
<li> Gerlach T, Zachoval R, Gruener N et al. (2001). Acute hepatitis C: Natural course and response to antiviral treatment. Hepatology 34: 341A.</li>
<li> Jaeckel E, Cornberg M, Wedemeyer H et al. (2001). Treatment of acute hepatitis C with interferon a2b. N Engl J Med 345: 1452-1457.</li>
<li> Hofer H, Watkins-Riedel T, Janata O et al. (2003). Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of viral load. Hepatology 37: 60-64.</li>
</ol>
</blockquote>
<center>
<hr width="100%"/>
<a href="mailto:reichen@ikp.unibe.ch"><img height="23" src="http://web.archive.org/web/20080517194314im_/http://www.ikp.unibe.ch/lab2/ba_email1.gif" width="120"/></a>
<a href="/cache?uri=https%3A%2F%2Fwww.ikp.unibe.ch%2Flab2%2Findex.html&amp;index=cw09&amp;raw"><img height="23" src="http://web.archive.org/web/20080517194314im_/http://www.ikp.unibe.ch/lab2/ba_home1.gif" width="120"/></a>
</center>
<hr width="100%"/>
<center>
   1998 
   <br/>Revised February 5
   <sup>th</sup> 2003
  </center>
</body>
</html>